---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-104304"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:05:55.212033+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM

## Summary
- Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.
- Interim analysis of progression-free survival anticipated after sufficient events from the 120 subjects.
- Sagimet expects FASCINATE-2 Phase 2b NASH biopsy results and Phase 1 hepatic impairment data in Q1 2024.
- Denifanstat is an oral FASN inhibitor; Sagimet licensed China rights to Ascletis in January 2019.

## SEC filing metadata
- accession: 0001104659-23-104304
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/0001104659-23-104304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/tm2327008d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-104304
- JSON: https://secwatch.observer/filing/0001104659-23-104304.json
- Plain text: https://secwatch.observer/filing/0001104659-23-104304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.